Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29843194 | 0.82 | KMT2A (0.66) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL3007964 | 0.82 | KMT2A (0.66) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL1033548 | 0.82 | KMT2A (0.66) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL2815639 | 0.81 | KMT2A (0.64) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL2103706 | 0.81 | KMT2A (0.64) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL19122497 | 0.81 | KMT2A (0.66) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL23917550 | 0.80 | KMT2A (0.63) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL17227611 | 0.79 | KMT2A (0.62) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL693455 | 0.78 | KMT2A (1.00) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL171727 | 0.77 | KMT2A (0.58) | KMT2AMEN1L3MBTL1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819667-B1 | SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8163735-B2 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | CTSF, CTSS, CSTB | KMT2A 3063/4885MEN1 4617/4885L3MBTL1 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.